Literature DB >> 33754155

Randomized Multi-Reader Evaluation of Automated Detection and Segmentation of Brain Tumors in Stereotactic Radiosurgery with Deep Neural Networks.

Shao-Lun Lu1,2, Fu-Ren Xiao3, Jason Chia-Hsien Cheng1,4,2, Wen-Chi Yang1,4, Yueh-Hung Cheng5, Yu-Cheng Chang5, Jhih-Yuan Lin5, Chih-Hung Liang5, Jen-Tang Lu5, Ya-Fang Chen6, Feng-Ming Hsu1,4.   

Abstract

BACKGROUND: Stereotactic radiosurgery (SRS), a validated treatment for brain tumors, requires accurate tumor contouring. This manual segmentation process is time-consuming and prone to substantial inter-practitioner variability. Artificial intelligence (AI) with deep neural networks have increasingly been proposed for use in lesion detection and segmentation but have seldom been validated in a clinical setting.
METHODS: We conducted a randomized, cross-modal, multi-reader, multi-specialty, multi-case study to evaluate the impact of AI assistance on brain tumor SRS. A state-of-the-art auto-contouring algorithm built on multi-modality imaging and ensemble neural networks was integrated into the clinical workflow. Nine medical professionals contoured the same case series in two reader modes (assisted or un-assisted) with a memory washout period of 6 weeks between each section. The case series consisted of ten algorithm-unseen cases, including five cases of brain metastases, three of meningiomas and two of acoustic neuromas. Among the nine readers, three experienced experts determined the ground truths of tumor contours.
RESULTS: With the AI assistance, the inter-reader agreement significantly increased (Dice similarity coefficient [DSC] from 0.86 to 0.90, P<0.001). Algorithm-assisted physicians demonstrated a higher sensitivity for lesion detection than un-assisted physicians (91.3% versus 82.6%, P=0.030). AI assistance improved contouring accuracy, with an average increase in DSC of 0.028, especially for physicians with less SRS experience (average DSC from 0.847 to 0.865, P=0.002). In addition, AI assistance improved efficiency with a median of 30.8%-time savings. Less-experienced clinicians gained prominent improvement on contouring accuracy but less benefit in reduction of working hours. By contrast, SRS specialists had a relatively minor advantage in DSC, but greater timesaving with the aid of AI.
CONCLUSIONS: Deep learning neural networks can be optimally utilized to improve accuracy and efficiency for the clinical workflow in brain tumor SRS.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

Entities:  

Keywords:  Artificial intelligence; Brain tumor; Deep learning; Randomization; Stereotactic radiosurgery

Year:  2021        PMID: 33754155     DOI: 10.1093/neuonc/noab071

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  4 in total

Review 1.  Machine learning in neuro-oncology: toward novel development fields.

Authors:  Vincenzo Di Nunno; Mario Fordellone; Giuseppe Minniti; Sofia Asioli; Alfredo Conti; Diego Mazzatenta; Damiano Balestrini; Paolo Chiodini; Raffaele Agati; Caterina Tonon; Alicia Tosoni; Lidia Gatto; Stefania Bartolini; Raffaele Lodi; Enrico Franceschi
Journal:  J Neurooncol       Date:  2022-06-28       Impact factor: 4.506

2.  Opportunities for integration of artificial intelligence into stereotactic radiosurgery practice.

Authors:  Rupesh Kotecha; Sanjay Aneja
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

3.  Deep learning approach based on superpixel segmentation assisted labeling for automatic pressure ulcer diagnosis.

Authors:  Che Wei Chang; Mesakh Christian; Dun Hao Chang; Feipei Lai; Tom J Liu; Yo Shen Chen; Wei Jen Chen
Journal:  PLoS One       Date:  2022-02-17       Impact factor: 3.240

4.  Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study.

Authors:  Shaohan Yin; Xiao Luo; Yadi Yang; Ying Shao; Lidi Ma; Cuiping Lin; Qiuxia Yang; Deling Wang; Yingwei Luo; Zhijun Mai; Weixiong Fan; Dechun Zheng; Jianpeng Li; Fengyan Cheng; Yuhui Zhang; Xinwei Zhong; Fangmin Shen; Guohua Shao; Jiahao Wu; Ying Sun; Huiyan Luo; Chaofeng Li; Yaozong Gao; Dinggang Shen; Rong Zhang; Chuanmiao Xie
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.